January 14, 2021 News by Forest Ray PhD Public-private Partnership Will Assess Therapy Potential, Effects of CBD Open Book Extracts (OBX) and Case Western Reserve University School of Medicine have partnered to investigate how cannabinoids like CBD affect brain cells, particularly in regard to neuroinflammation, according to an OBX press release. CBD (cannabidiol) and other cannabinoids, such as THC (tetrahydrocannabinol), have attracted interest for…
May 12, 2020 News by Marta Figueiredo, PhD Spasticity Scales May Not Reflect Sativex Benefits in MS Patients, Study Suggests SativexĀ (nabiximols) eases spasticity-associated symptoms in multiple sclerosisĀ (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patientsā responses to Sativex and to…
March 18, 2020 News by David Melamed, PhD MS Patients Find Cannabis Helpful for Easing Pain, Spasticity, Study Reports About 85% of people with multiple sclerosis (MS) usingĀ cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in…
March 3, 2020 News by Marta Figueiredo, PhD #ACTRIMS2020 – EHP-101 Shows Promise in Early Studies; Phase 2 Trial Ahead Emerald Health Pharmaceuticalsā investigational cannabidiol-derived EHP-101 continues to show potential to ease inflammation and myelin loss (demyelination) ā a hallmark of multiple sclerosis (MS) ā according to data from healthy volunteers and a mouse model of MS. The data support the advance of EHP-101’s clinical development into…
December 9, 2019 News by Marisa Wexler, MS Atlas Biotechnologies to Fund Research into Cannabis Treatment for MS, Similar Diseases Atlas BiotechnologiesĀ will fund and provide support to three research projects at the University of AlbertaĀ to possibly identify cannabis component(s) that could help people with neurological diseases likeĀ multiple sclerosis (MS). The cannabis plant produces hundreds of biological compounds, the best-known being tetrahydrocannabinol (THC) ā the psychoactive compound primarily…
November 20, 2019 News by Alice MelĆ£o, MSc MMJ Enters Agreement to Produce Cannabis-based Capsules for Clinical Trials in MS and Huntingtonās MMJ International HoldingsĀ announced that it has entered into an agreement for the production of its proprietary cannabis-based gel capsule ā a product mix of tetrahydrocannabinol (THC) and cannabidiol (CBD) ā in compliance with guidelines set by the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).
October 31, 2019 News by Ana Pena PhD Medicinal Cannabinoids Not Effective for Mental Disorders, Small Relief on MS Anxiety, Analysis Suggests A joint analysis of 83 studies, involving 3,000 people, concluded that there is “scarce evidence” to say that the use of medicinal cannabinoids ā chemical compounds in the cannabis plant ā is able to improve mental health conditions. However, the use of pharmaceutical tetrahydrocannabinol (THC) may lead to…
August 14, 2019 News by Joana Carvalho, PhD US Agency Asked to OK Cannabinoid Shipments from Canada to Support Studies in MS, MMJ Announces MMJ International Holdings, a pharmaceutical company whose focus is plant-derived cannabis products for therapeutic purposes, has requested permission to ship tetrahydrocannabinol (THC) and cannabidiol (CBD) from Canada to the U.S. to be used in upcoming clinical trials for people with multiple sclerosis (MS) and Huntington’s disease. MMJ-001…
April 23, 2019 News by Ana Pena PhD Main Ingredient in Potential MS Therapy EHP-101 Not a Controlled Substance, DEA Rules The U.S. Drug Enforcement Administration (DEA)Ā has determined that theĀ cannabidiol-based active ingredient of EHP-101, an investigational oral treatment for multiple sclerosis (MS)Ā under development by Emerald Health Pharmaceuticals (EHP), should not be classified…
February 28, 2019 News by Santiago Gisler Axim Improves Delivery of Cannabinoids in Chewing Gums Axim Biotechnologies announced that it has succeeded in microencapsulating cannabinoids (chemical compounds in cannabis) into the companyās patented chewing gums, which are used to treat several disease symptoms, including pain and spasticity associated withĀ multiple sclerosis (MS). Since the active cannabinoids are degradable in the body, the company needed…
January 2, 2019 News by Jose Marques Lopes, PhD Top 10 Multiple Sclerosis Stories of 2018 Multiple Sclerosis News Today brought you daily coverage of key findings, treatment developments, andĀ clinical trials related to multiple sclerosis (MS) throughout 2018. We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2019. Here are the top 10 most-read articles of…
December 12, 2018 News by Mary Chapman GB Sciences, LSU Partner on Cannabinoid Research and Development Project for MS, Other Diseases As debate continues about the effects of medical marijuana on multiple sclerosis (MS) and other diseases, cannabis companyĀ GB SciencesĀ and Louisiana State UniversityĀ (LSU) have agreed on a cannabinoid research and development project. This collaboration between a public and a private enterprise is a first in the therapeutic cannabis…
June 7, 2018 News by Alice MelĆ£o, MSc #CMSC2018 ā Pharmacist Discusses Advances, Challenges in Cannabinoids Research to Treat MS Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But there is still much to be done to enhance their use and accessibility to patients who may benefit from these therapies, according to…
May 22, 2018 News by Diogo Pinto Sativex Can Improve Driving Ability of MS Patients, Study Says Sativex, a cannabis-based anti-spasticity medicine commercialized as oromucosal spray by GW Pharmaceuticals, improves the driving ability of patients with multiple sclerosis (MS), according to researchers. The findings were published in the journal Brain and Behavior, in a study titled āThe influence of THC:CBD oromucosal spray…
February 15, 2018 News by Alice MelĆ£o, MSc Clinicians Who Prescribe Cannabis Should ‘Start Low and Go Slow,’ Study Advises Use of medicinal cannabis may pose risks as it may trigger psychiatric problems, but also because it lacks standardized chemical composition, according to a study published in the Journal of the American Osteopathic Association. With the legalization of cannabis in some states for medicinal and recreational proposes, additional pressure…
January 8, 2018 News by Patricia Silva, PhD MMJ Files Patent on Part-cannabinoid and Part-non-cannabinoid Treatment for MS MMJ International HoldingsĀ is seeking a patent for a part-cannabinoid and part-non-cannabinoid treatment forĀ multiple sclerosisĀ and other diseases. The company said in aĀ news releaseĀ that it filed the patent request ahead of Phase 2 clinical trials of the formulation. Ā The therapy was developed by MMJ Bioscience, anĀ affiliate of MMJ International…
November 29, 2017 News by Patricia Silva, PhD MMJ Files US Patent for Multiple Sclerosis Cannabinoid Treatment MMJ International Holdings has applied to the U.S. Patent and Trademark Office (USPTO) for new pharmaceutical compounds and methods to treat and prevent symptoms associated with multiple sclerosis (MS) and other diseases responsive to cannabinoids. The patent covers MMJ BioScienceās intellectual property portfolio, which comprises several patent families…
November 14, 2017 News by Patricia Silva, PhD MMJ Hires Lead Investigator for Phase 2 Trials of Medicinal Cannabis to Treat Progressive MS MMJ BioScience, an affiliate of medical cannabis research company MMJ International Holdings, has hired a principal investigator to lead clinical trials exploring potential therapeutic applications of cannabinoids inĀ progressive multiple sclerosis (MS). Dr. Bianca Weinstock-Guttman, a neurology professor at the State University of New York at Buffalo,Ā is executive director…
February 23, 2017 News by Patricia Silva, PhD Brazil Allows HempMeds to Import RSHO Cannabidiol for MS Treatment The Brazilian government has authorizedĀ HempMeds Brasil, a unit of California-basedĀ Medical Marijuana, to import the parent company’sĀ hemp cannabidiol (CBD) oil flagship product ā known as Real Scientific Hemp Oil (RSHO) āĀ for the management of multiple sclerosis (MS) symptoms. This is the first time Brazil’s National Health Surveillance Agency…
February 7, 2017 News by Patricia Silva, PhD 95% of MS Patients Open to Marijuana Treatment, 73% Have Tried It Ninety-five percent ofĀ multiple sclerosis (MS)Ā patients believe medical marijuana should be a treatment option, according to aĀ GeneFoĀ online survey. The survey also showed that almost 73 percent had tried it, even though about half said they hadn’t received information from a doctor about its benefits and risks. A National…
January 17, 2017 News by Patricia Silva, PhD Cannabis Compounds Ease Spasticity in MS, National Academies’ Report States CertainĀ cannabinoids reduce spasticity symptoms inĀ multiple sclerosis (MS) patients, according toĀ aĀ reportĀ from the National Academies of Sciences, Engineering, and MedicineĀ thatĀ scrutinized published research about the benefits and hazards of cannabis and cannabinoid use. Cannabinoids also show proven effectĀ in other areas that may be importantĀ to MS patients, but they are linked…
July 5, 2016 News by InĆŖs Martins, PhD Tremors Linked to MS Poorly Treated with Symptomatic Medication, Study Finds Disabling tremors can affect as many as half of all peopleĀ with multiple sclerosis (MS), but they are inadequately treated because of limited therapeutic options and are not sufficiently being studied, researchers at theĀ University of Alabama at BirminghamĀ reported. Their report, “Symptomatic Management of Multiple Sclerosis-Associated Tremor Among…
October 23, 2015 News by Charles Moore Cannabis-Derived Sativex for MS-Related Spasticity Reported to Be Effective and Safe Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) ā held in Barcelona October 7ā10, 2015 ā supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids…